Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes. In the European Union, its use is limited to complementing insulin therapy. As of 2017 it is unclear if they affect a person's risk of death. It is provided in an autoinjector containing fourteen doses and is injected subcutaneously.
Lixisenatide should not be used for people who have problems with stomach emptying. Lixisenatide delays emptying of the stomach, which may change how quickly other drugs that are taken by mouth take effect.
蘇州默迪夫生物科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!
默迪夫生物